Structuring Milestones and Contingent Payments in Biotech, Pharma, and Medtech M&A and Collaborations: U.S. and European Trends
McDermott Will & Emery, JSB-Partners and SRS Acquiom presented a complimentary Life Sciences Roundtable and evening reception. JSB-Partners presented recent data from their experience managing over 100 life sciences M&A deals, and the panel addressed the key issues and recent trends involved in structuring milestone and contingent payments in collaboration and M&A agreements in both the United States and Europe.
The panel addressed the following critical issues related to pharmaceutical and medtech deal-making:
- Key factors to consider when structuring and drafting clinical, regulatory and sales-based milestone payments
- Drafting “due diligence” obligations, and the definition of “commercially reasonable efforts”
- Recent developments in life sciences litigation involving milestone payments, earn-outs, contingent consideration and royalty payments
Michel Gouy, Partner, JSB-Partners
Amanda Jackson, Director, Business Development, SRS Acquiom
Anthony Paronneau, Partner, McDermott Will & Emery LLP
Emmanuelle Trombe, Partner, McDermott Will & Emery LLP
Kristian A. Werling, Partner, McDermott Will & Emery LLP
For more information, please contact McDermott Events.